148 related articles for article (PubMed ID: 36831030)
1. Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of
Jain M; Tivtikyan A; Kamalov D; Avdonin S; Rakhmatullin T; Pisarev E; Zvereva M; Samokhodskaya L; Kamalov A
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831030
[TBL] [Abstract][Full Text] [Related]
2. Regulatory region mutations of
Xing X; Yuan X; Liu T; Dai M; Fan Y; Liu C; Strååt K; Björkholm M; Xu D
J Cancer; 2021; 12(13):3853-3861. PubMed ID: 34093793
[No Abstract] [Full Text] [Related]
3. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N
Front Oncol; 2020; 10():755. PubMed ID: 32509577
[TBL] [Abstract][Full Text] [Related]
6. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of
Garinet S; Pignot G; Vacher S; Le Goux C; Schnitzler A; Chemlali W; Sirab N; Barry Delongchamps N; Zerbib M; Sibony M; Allory Y; Damotte D; Bieche I
Mol Cancer Res; 2019 Feb; 17(2):469-475. PubMed ID: 30401719
[TBL] [Abstract][Full Text] [Related]
8. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F
Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237
[TBL] [Abstract][Full Text] [Related]
9.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
10. Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study.
Jain M; Kamalov D; Tivtikyan A; Balatsky A; Samokhodskaya L; Okhobotov D; Kozlova P; Pisarev E; Zvereva M; Kamalov A
Mol Clin Oncol; 2021 Dec; 15(6):253. PubMed ID: 34712485
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
12. Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR.
Tan D; Jiang W; Hu R; Li Z; Ou T
Cancer Med; 2023 May; 12(10):11503-11512. PubMed ID: 37081791
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
14. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder.
Singh P; Singh A; Gupta N; Raja KD; Singh P; Agarwal S; Sharma A
Mol Cell Biochem; 2022 Sep; 477(9):2173-2182. PubMed ID: 35445913
[TBL] [Abstract][Full Text] [Related]
18. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
Corless BC; Chang GA; Cooper S; Syeda MM; Shao Y; Osman I; Karlin-Neumann G; Polsky D
J Mol Diagn; 2019 Mar; 21(2):274-285. PubMed ID: 30827467
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
20. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
